Home Circulating tumor cells as emerging tumor biomarkers in breast cancer
Article
Licensed
Unlicensed Requires Authentication

Circulating tumor cells as emerging tumor biomarkers in breast cancer

  • Evi S. Lianidou EMAIL logo and Athina Markou
Published/Copyright: July 29, 2011

Abstract

Circulating tumor cells (CTCs) provide unique information for the management of breast cancer patients, since their detection and monitoring is useful for prognosis, prediction of response to therapy, or monitoring clinical course in patients with localized or metastatic disease. Currently, the most practical application of CTCs is monitoring of patients with metastatic disease. Elevated CTC levels prior to initiation of a new systemic therapy are associated with a worse prognosis while persistently elevated CTC levels strongly suggest that the therapeutic regimen with which the patient is being treated is not working. New areas of research are directed toward developing novel sensitive assays for CTC molecular characterization. Molecular characterization of CTCs is very important for the future use of CTCs as targets of novel therapies. This review has focused on the presentation of recent data showing that CTCs are emerging as novel tumor biomarkers for prognostic and predictive purposes in breast cancer.


Corresponding author: Dr. Evi S. Lianidou, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens 15771, Greece Phone: +30 210 7274319, Fax: +30 210 7274750

Received: 2011-3-1
Accepted: 2011-5-2
Published Online: 2011-07-29
Published in Print: 2011-10-01

©2011 by Walter de Gruyter Berlin Boston

Articles in the same Issue

  1. Editorial
  2. Laboratory medicine: an essential partner in the care of cancer patients
  3. Reviews
  4. Circulating tumor cells as emerging tumor biomarkers in breast cancer
  5. Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer
  6. Increased plasma concentrations of tumour markers in the absence of neoplasia
  7. Recent progress and clinical importance on pharmacogenetics in cancer therapy
  8. Genetics and Molecular Diagnostics
  9. Genotyping of the hemochromatosis HFE p.H63D and p.C282Y mutations by high-resolution melting with the Rotor-Gene 6000® instrument
  10. General Clinical Chemistry and Laboratory Medicine
  11. Mapping point-of-care performance using locally-smoothed median and maximum absolute difference curves
  12. The use of inflammatory markers as a method for discharging patients post hip or knee arthroplasty
  13. Significant elevation of plasma pentraxin 3 in patients with pelvic inflammatory disease
  14. Combined effects of coffee consumption and serum γ-glutamyltransferase on serum C-reactive protein in middle-aged and elderly Japanese men and women
  15. Multicentre comparison of free thyroid hormones immunoassays: the Immunocheck study
  16. Comparative evaluation of capillary zone electrophoresis and HPLC in the determination of carbohydrate-deficient transferrin
  17. Determinants of blood levels of some thrombogenic biomarkers in healthy Arab adolescent subjects
  18. Analytical performance of a multiplexed, bead-based cytokine detection system in small volume samples
  19. Diagnostic utility of a soluble cytokeratin 18 assay for gastrointestinal graft-vs.-host disease detection
  20. Cancer Diagnostics
  21. The correlation between zinc and insulin-like growth factor 1 (IGF-1), its binding protein (IGFBP-3) and prostate-specific antigen (PSA) in prostate cancer
  22. Differential expression of CDC25 phosphatases splice variants in human breast cancer cells
  23. Serum APRIL, a potential tumor marker in pancreatic cancer
  24. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma
  25. Infectious Diseases
  26. New serum biomarkers for detection of tuberculosis using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry
  27. Cardiovascular Diseases
  28. Association of a functional polymorphism in the MMP7 gene promoter with susceptibility to vulnerable carotid plaque in a Han Chinese Population
  29. Diabetes
  30. Glycated albumin may be a possible alternative to hemoglobin A1c in diabetic patients with anemia
  31. A simple micro-photometric method for urinary iodine determination
  32. Letters to the Editor
  33. Clinically needed sensitivity for very low levels of Factor XIII: not yet proven for a new functional assay
  34. Apolipoprotein A5-12238 T>C gene polymorphism and risk factors for metabolic syndrome in the Guo Shan Yao and the Han populations
  35. Congress Abstracts
  36. 10.1515/CCLM.2011.738
  37. 1st National Congress of Laboratory Medicine
Downloaded on 12.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2011.628/html
Scroll to top button